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Welcome to the 2012 edition of the ABEM “Clinical & Molecular Endocrine Case Reports”. This special issue aims at describing clinical cases in which mo-
lecular research was performed, thus opening opportunities for the publication of 
novel mutations, and for the presentation of clinical particularities in patients with 
mutations that have already been described. Previous editions of 2008 and 2010 were 
highly accessed, and had great repercussion. We hope the current edition also fulfills 
everybody’s expectations, or maybe surpasses them.
The advances in molecular genetics methods, in the recent decades, have allowed 
the identification of genetic components in several endocrinopathies. Many of these 
discoveries led to important improvements in the diagnosis and treatment of these 
conditions. One such example is MODY. Alterations in ten different genes have been 
associated with this disease, and marked differences in the clinical presentation of dia-
betes caused by mutations in each of these genes were noted. Patients with mutations 
in GCK have mild hyperglycemia, and pharmacological treatment is rarely necessary. 
In contrast, in individuals harboring mutations in HNF1A, hyperglycemia is progres-
sive, and usually requires pharmacological treatment (1,2). This issue presents two 
studies, by DellaManna and cols. (3) and Caetano and cols. (4), in Brazilian patients 
with MODY 2 and harboring GCK mutations. Also in relation to the development 
of hyperglycemia in a monogenic context, a case of maternally-inherited diabetes and 
deafness (MIDD) with hyporeninemic hypoaldosteronism by Mory and cols. (5) is 
found in this edition.
 In contrast, type 2 diabetes is notably a multifactorial and polygenic disease. The 
association between polymorphisms in the TCF7L2 gene and type 2 diabetes have 
been described in different populations in the recent years, showing a possible role 
of this gene in the predisposition to the disease. In this edition, such association was 
investigated in a Brazilian population by Barra and cols. (6).
A number of genetic alterations have been correlated with disorders in growth and 
sexual development, and in some cases, the genetic profile may predict the phenotype 
and clinical outcome. From chromosome anomalies to point mutations, studies by 
Maciel-Guerra and cols. (7), Keselman and cols. (8), Castro and cols. (9), Beneduzzi 
and cols. (10), Guaragna-Filho and cols. (11), Nishi and cols. (12), and Battistin and 
cols. (13) concisely address different settings of growth and/or sexual development in 
which molecular genetics were important tools for a proper clinical approach. Thyroid 
diseases were also addressed in this issue by Scaglia and cols. (14) in a case of congeni-
tal hyperthyroidism, and by Secchi and cols. (15) in a patient with transient congenital 
hypothyroidism. The study by Geraldo and cols. (16) illustrates the contribution of 
microRNA detection strategies in the prediction of outcomes, by describing a patient 
with an aggressive papillary thyroid carcinoma.  
In pituitary diseases, better knowledge of the mechanisms involved in tumorige-
nesis may provide more effective medical therapy. The association of mutations in 
the AIP gene in patients with familial pituitary adenomas has pointed out a possible 
role of AIP protein alterations in the development of sporadic pituitary tumors. In 
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this issue, Kasuki and cols. (17) investigated the AIP 
expression in GH-secreting tumors in correlation with 
response to medical treatment. Boguszewski and cols. 
(18) describe an interesting case in which  the two types 
of multiple endocrine neoplasm coexist, and discuss the 
genetic findings associated with this condition, whereas 
multiple endocrine neoplasia type 2 is revisited by Blom 
and cols. (19) in a description of the rare S891A RET 
mutation in a patient with medullary thyroid carcino-
ma. In addition, genetic studies in oncogenic osteoma-
lacia by Chang and cols. (20), and in Frasier (Guaragna 
and cols. [21]), Cowden’s (Lima and cols. [22]) and 
hyperinsulinism/hyperammonemia (Corrêa-Giannella 
and cols. [23]) syndromes are presented in this issue. 
In the past, knowledge about molecular genetics 
was important in the management of only a restricted 
group of patients. Currently, this strategy has become 
critical for proper monitoring of a large number of pa-
tients in different settings (24). Accordingly, the prac-
titioner should be familiar with the indications and po-
tential limitations of genetic testing. 
We are honored to participate as invited editors in 
this Special Edition of ABEM, having the opportuni-
ty of getting in contact with high-quality articles. We 
would like to thank the authors who contributed to 
this edition submitting their manuscripts; the reviewers 
for their constructive comments and suggestions; and 
the co-editor of ABEM, Alexander A. L. Jorge, for his 
invaluable assistance. We hope this edition represents 
an opportunity to update and acquire new information 
in such an exciting area of  knowledge.
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